Abstract:Background: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia encountered in clinical practice, and it is associated with an increased risk of mortality, stroke, and peripheral embolism. The risk of stroke in AF is heterogeneous and dependent on underlying clinical conditions included in current risk stratification schemes. Recently, the CHA2DS2-VASc score has been incorporated into guidelines to encompass common stroke risk factors observed in routine clinical practice. The aim of this study was to study the predictive value of CHA2DS2-VASc score on the prognosis of patients with AF to determine the correlation of major complications including cerebral infarction and intracranial hemorrhage in patients with AF with oral anticoagulant and antiplatelet aggregation drugs and to identify the risk factors for all-cause mortality. Methods: A prospective study was conducted on 181 patients with AF who underwent physical examinations at Hai'an Qutang Central Hospital from January 2020 to December 2020. The patient's general condition, chronic disease history, CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 years (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 years, and sex category (female)] score, left ventricular ejection fraction (LVEF), lipid metabolism, and oral anticoagulant and antiplatelet aggregation medication during physical examination were recorded. By using telephone meetings to complete the follow-up, we tracked the patient's cerebral infarction, intracranial hemorrhage, and survival status within 2 years of follow-up, statistically analyzed the relationship between AF complications and medication, and grouped patients with AF based on the CHA2DS2-VASc score to evaluate its predictive ability for mortality outcomes in these patients. Results: The patients were divided into four groups according to the medication situation, and the incidence of cerebral infarction in the combination group was significantly lower than that in the non-medication group (0.0% vs. 19.2%; P<0.01). The incidence of intracranial hemorrhage in the combination group was significantly higher than that in the non-drug group (13.8% vs. 0.0%; P<0.01). The logistic regression model indicated that patients with a history of cerebral infarction had an increased risk of death compared to those without a history of cerebral infarction [odds ratio (OR) =7.404; 95% confidence interval (CI): 2.255-24.309]. After grouping according to the CHA2DS2-VASc score, we found that there was a significant difference in the 2-year survival rate between patients with CHA2DS2-VASc score <5 and those with a score ≥5 (P<0.01). The characteristic curve analysis of the participants showed that the CHA2DS2-VASc score had good predictive ability for all-cause mortality in patients with AF (area under the curve =0.754), with a cutoff value of 4, a sensitivity of 62.50%, a specificity of 86.06%, and a 95% CI of 0.684-0.815. Conclusions: The CHA2DS2-VASc score demonstrated high predictive value for all-cause mortality in patients with AF.

Pacemaker-detected atrial fibrillation burden and risk of ischemic stroke or thromboembolic events-A cohort study.

Atrial Fibrillation Burden Detected by Dual-Chamber Pacemakers As a Predictor for Cardiac Outcomes: A Retrospective Single-Center Cohort Study.

A retrospective study of atrial fibrillation after DDD pacemaker implantation

The Risk Factors of New-Onset Atrial Fibrillation after Pacemaker Implantation

Value of Combining Left Atrial Diameter and Amino-terminal Pro-brain Natriuretic Peptide to the CHA2DS2-VASc Score for Predicting Stroke and Death in Patients with Sick Sinus Syndrome after Pacemaker Implantation.

ANALYSIS OF PREDICTORS OF ATRIAL FIBRILLATION AFTER PACEMAKER IMPLANTATION

P1360Association between left atrial appendage dysfunction and thromboembolic risk in nonvalvular atrial fibrillation

The incidence and risk factors of atrial high-rate episodes in patients with a dual-chamber pacemaker

Abstract 14262: Atrial Fibrillation Burden and Clinical Outcomes in Patients With Cardiac Implanted Electronic Devices

Atrial High-Rate Event Incidence and Predictors in Patients With Permanent Pacemaker Implantation

New Perspective on the Risk Markers for Left Atrial Thrombosis in Patients with Atrial Fibrillation.

Association of left pulmonary vein trunk and subclinical atrial fibrillation in patients with cardiac implantable electronic device

Impact of Premature Ventricular Complex Burden on Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation

Interatrial Septal Pacing to Suppress Atrial Fibrillation in Patients with Dual Chamber Pacemakers: A Meta-Analysis of Randomized, Controlled Trials

Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events

Performance of Atrial Fibrillation Burden Trends for Stroke Risk Stratification

High premature atrial complex burden and risk of renal function decline

The predictive value of CHA2DS2-VASc score on the prognosis of patients with atrial fibrillation based on a prospective cohort study

Varying effect of atrial fibrillation ablation in patients with heart failure with preserved ejection fraction according to CHA2DS2-VASc score

Atrial Fibrillation, Atrial Myopathy, and Thromboembolism: The Additive Value of Echocardiography and Possible New Horizons for Risk Stratification

Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry